Birth Defects Res A Clin Mol Teratol by Shaw, Gary M. et al.
One-carbon metabolite levels in mid-pregnancy and risks of 
conotruncal heart defects
Gary M. Shaw1,*, Wei Yang1, Suzan L. Carmichael1, Stein Emil Vollset2, Charlotte A. 
Hobbs3, Edward J. Lammer4, and Per M. Ueland5
1Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
2Norwegian Institute of Public Health and University of Bergen, Bergen, Norway
3University of Arkansas, Little Rock AK
4Children’s Hospital Oakland Research Institute, Oakland CA
5Department of Clinical Science, University of Bergen, and Laboratory of Clinical Biochemistry, 
Haukeland University Hospital, Bergen, Norway
Abstract
Background—Evidence exists for an association between use of vitamin supplements with folic 
acid in early pregnancy and reduced risk for offspring with conotruncal heart defects. A few 
observations have been made about nutrients related to one-carbon metabolism other than folate. 
Our prospective study attempted to extend information on nutrition and conotruncal heart defects 
by measuring analytes in mid-pregnancy sera.
Methods—This study included data from a repository of women’s mid-pregnancy serum 
specimens based on screened pregnancies in California from 2002–07. Each woman’s specimen 
was linked with delivery information to determine whether her fetus had a conotruncal heart 
defect or another structural malformation, or was nonmalformed. We identified 140 conotruncal 
cases and randomly selected 280 specimens as nonmalformed controls. Specimens were tested for 
a variety of analytes including: homocysteine, methylmalonic acid, folate, vitamin B12, pyridoxal 
phosphate, pyridoxal, pyridoxic acid, riboflavin, total choline, betaine, methionine, cysteine, 
cystathionine, arginine, asymmetric and symmetric dimethylarginine.
Results and Conclusions—We did not observe statistical evidence for substantial differences 
between cases and controls for any of the measured analytes. Analyses specifically targeting B-
vitamins also did not reveal differences between cases and controls.
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Congenital heart defects comprise the most common group of human malformations, 
affecting about 1% of births (1,2). Despite their sizable contribution to child morbidity and 
infant mortality, etiologies for the majority of heart defect phenotypes remain unknown. 
Within the overall group of heart defects, those known as conotruncal defects are some of 
the more common phenotypes.
One promising clue to etiologies of conotruncal heart defects has been that women who use 
vitamins containing folic acid in early pregnancy are at approximately a 30% reduced risk to 
deliver offspring with these heart defects (3–7), but not in all studies (8). Folic acid has been 
the focus for the preponderance of inquiries about periconceptional nutrition and risks of 
heart defects, and birth defects more generally. There is some support from four small 
studies (9–14) that indicate compromised homocysteine remethylation and lack of methyl 
group nutrients may contribute to risks of certain heart defects.
Methylation of DNA is influenced by dietary contributions of methyl donors such as folate 
and vitamin B12. A less than optimal methyl-donor supply and DNA methylation has 
certainly been a suggested area for research efforts for certain birth defects (15). A 
Netherlands study (9) observed that median fasting plasma homocysteine was higher and 
that mean B12 levels were lower, six months post delivery in mothers of children with heart 
defects. Similarly, an Arkansas study (10–12) observed post-partum plasma concentrations 
that were substantially higher in homocysteine, substantially lower in methionine, and lower 
in folate and B12, in mothers who had delivered babies with heart defects compared to 
mothers who delivered babies without birth defects. These observations included all heart 
defects combined, as well as specific phenotypes including conotruncal and septal defects. A 
third study (13) reported an increased risk for heart defects among Dutch women who had 
compromised B12 status and who had the methionine synthase reductase MTRR 66GG 
genotype. A fourth study (14) found an elevated risk of heart defects among Dutch mothers 
with lower B12 levels in the postpartum period and who had the transcobalamin II 
(rs1801198) genotype 776GG. A fifth study from a single clinic and a small case population 
found elevated homocysteine levels in amniotic fluid of women with fetuses that had various 
isolated congenital heart defects (16).
These observations led us to explore whether women’s mid-pregnancy measurements, rather 
than post-partum measurements, of selected serum analytes, some indicative of the methyl-
donor supply, were associated with the risk of conotruncal heart defects in offspring from a 
large population-base in California.
Methods
This study included data from a large and unique mid-pregnancy serum specimen bank of 
pregnancies in California. Specimens were collected from approximately 70% of women 
during the 15th–18th week of pregnancy. These sera were collected from women who 
resided in selected regions of California (Orange, San Diego, and Central Valley counties) 
as part of the California prenatal screening program that offers three types of screening tests 
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to pregnant women in order to identify individuals who are at increased risk for carrying a 
fetus with a specific birth defect (http://www.cdph.ca.gov/programs/pns/Pages/default.aspx). 
The collection and processing of specimens was as follows: 1) samples were taken at draw 
stations using BD™ Vacutainer 3.5 mL serum separator tubes with no anticoagulants or 
preservatives and centrifuged within 30 minutes; 2) samples were received by designated 
clinical laboratories from draw stations at room temperature, on average 3.0 days after draw; 
3) AFP screening assays were run on samples usually on the day received; 4) samples were 
refrigerated up to 7 days if further testing was necessary; 5) samples were sent on cold packs 
via overnight mail to the serum storage bank; and 6) samples were aliquoted, labeled with 
barcodes, and frozen at −70°C within an average of 3.5 days of receipt at the serum storage 
bank.
Each woman’s serum specimen was linked with delivery outcome information to determine 
whether her fetus had a conotruncal heart defect, any other structural malformation 
ascertained by the California Birth Defects Monitoring Program (17), or was born 
nonmalformed. The study included pregnancies screened in the period 2002–2007. Case 
information was abstracted from multiple hospital reports and medical records. Infants 
diagnosed with single gene disorders or chromosomal aneusomies (based on information 
gathered from chart reviews) were ineligible. Cases were limited to conotruncal heart 
defects, specifically d-transposition of the great arteries (dTGA) and tetralogy of Fallot 
(TOF). For each case, anatomic and physiologic features were confirmed by reviewing 
echocardiography, cardiac catheterization, surgery, or autopsy reports. 140 infants with 
conotruncal defects were identified.
We also randomly selected 280 women (based on a 2:1 frequency with case infants) who 
contributed mid-pregnancy specimens that were collected during the same time period and 
delivered nonmalformed infants (controls). Thus, this was a nested case-control study. All 
samples were obtained with approval from the California Health and Welfare Agency 
Committee for the Protection of Human Subjects.
Serum specimens for 420 cases and controls were sent on cold packs to BEVITAL AS, 
Bergen, Norway (www.bevital.no) for analyte measurements. Analytes measured were: total 
homocysteine, methylmalonic acid, folate, vitamin B12, pyridoxal phosphate, pyridoxal, 
pyridoxic acid, pyridoxine, riboflavin, total choline, betaine, methionine, total cysteine, 
cystathionine, asymmetric dimethylarginine, symmetric dimethylarginine, serine, glycine, 
dimethylglycine, sarcosine, cystathionine, tryptophan, kynurenine, arginine, homoarginine, 
neopterin, 3-Hydroxykynurenine, kynurenic acid, xanthurenic acid, anthranilic acid, 3-
Hydroxyanthranilic acid, quinolinic acid, nicotinic acid, nicotinamide, N1-
methylnicotinamide, and creatinine.
To assess cigarette smoking exposures, the metabolite cotinine was measured. No smoke 
exposure was defined as values <5 nmol/L and any smoke exposure was defined as ≥5 
nmol/L. Details about all laboratory assays except total choline can be found elsewhere 
(18,19). Total choline was measured after conversion of choline esters to free choline in the 
presence of phospholipase D. A serum sample of 45 µL was mixed with 18 µL solution 
containing phospholipase D (Sigma Chemical Company, 2.8 U/µL), CaCl2 (86 mM) and 
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Triton (0.44%). Then, 30 µL dithioerythritol (147mM) and 60 µL TCA containing 400 µM 
d7Choline were added to the incubation mixture. After centrifugation, the supernatant was 
analyzed by LC-MS/MS using a method optimized for the determination of free choline 
(20). Laboratory analyses were performed blind to case and control status.
We compared mean levels of analytes between cases and controls with t-tests. We also 
estimated risks using odds ratios and 95% confidence intervals (SAS 9.3). Models were 
constructed to assess effects associated with categories of the measured analytes. 
Specifically, we categorized measures as <25th percentile, 25th–74th percentile, and ≥75th 
percentile based on the distribution of each analyte among controls. The 25th–74th 
percentile was used as the reference group. We analyzed data for linear (logistic regression) 
and nonlinear (spline regression) effects and found no evidence for the latter. Available from 
intake forms associated with the screening program were the demographic factors maternal 
race/ethnicity (Hispanic; white, nonHispanic; Asian; Black; other) and maternal age (<25; 
25–29; 30–34; and >34 years). These factors along with cigarette smoke exposure defined 
by cotinine levels were considered as covariates in some analyses.
Results
Table 1 shows similar racial/ethnic and age distributions between cases and controls, 
although case mothers were slightly more frequently nonHispanic white and older than were 
control mothers. Table 2 shows means and standard deviations of each measured analyte. 
We observed no statistically significant (p≤0.05) difference in mean levels between cases 
and controls for any analyte.
Given that comparisons of mean analyte values may not adequately reveal effects that could 
be associated with values toward the tails of the distribution, we explored lower and upper 
quartiles (cutpoints defined by the control distribution). As shown in Table 3, with the 
exception of low sarcosine (odds ratio=0.5, [0.3–0.8]), low symmetric dimethylarginine 
(odds ratio=1.8, [1.1–2.9]), and low folate (odds ratio=0.5, [0.3–0.9]), the many estimated 
effects (odds ratios) showed little evidence for associations. Analyses adjusted for maternal 
race/ethnicity and age are shown but crude analyses were not substantially different. 
Cotinine was not included in these analyses owing to the fact that most values for this 
analyte were zero. Analyses that excluded women with nonzero cotinine measures (cigarette 
smoking exposure, 15 case and 33 control women) did not produce substantially different 
results.
We simultaneously investigated five B-vitamin-related analytes, i.e., pyridoxal phosphate, 
riboflavin, betaine, vitamin B12, and folate. Compared to women whose levels were not in 
the lowest quartile for any of these measures, women whose levels included at least one low 
quartile measure showed an odds ratio of 0.9 (0.6—1.6) adjusted for maternal age and race/
ethnicity. Women with two or more low quartile measures showed similar effects (odds 
ratio=0.9 (0.5–1.4).
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In this prospective study, we examined potential associations between several gestational 
serum analytes, most of which are related to one-carbon metabolism B-vitamin status, and 
risk of conotruncal heart defects. Overall, these data did not show meaningful differences in 
mid-pregnancy analyte serum levels between women whose pregnancies involved 
conotruncal heart defects and those whose pregnancies did not involve structural 
malformations. Not observing an association with serum folate may be explained by the fact 
that women in this study were from a population whose food supply was fortified with folic 
acid and that most were also likely taking prenatal supplements containing folic acid as well 
as some of the other measured nutrients (e.g., vitamin B12) at the time of serum sampling.
Previous studies by our group found that lower mid-pregnancy serum choline (a one-carbon 
donor) levels were associated with elevated risks of NTDs (21) and decreased risks for CLP 
(22). Here we did not recapitulate such an association between low or high choline levels 
and conotruncal heart defects. Experimental data in mice have indicated an association 
between dietary deficiencies in choline with elevated risks of ventricular septal defects (23).
Several previously reported observations led us to explore whether women’s mid-pregnancy 
measurements of selected serum analytes were associated with the risk of conotruncal heart 
defects in offspring, particularly those associated with one-carbon metabolism. These 
observations included a Netherlands study (9) that found median fasting plasma 
homocysteine was higher and that mean B12 levels were lower, in mothers who delivered 
children with heart defects, an Arkansas study (10–12) that found post-partum plasma 
concentrations that were substantially higher in homocysteine, substantially lower in 
methionine, and lower in folate and B12, in mothers who had delivered babies with heart 
defects compared to mothers who delivered babies without birth defects, and a Dutch study 
(13) that found an increased risk for heart defects among women who had compromised B12 
status. These existing studies differ with the current study in two important ways. First, our 
study focused on the specific phenotype of conotruncal heart defects rather than the larger 
more heterogeneous group of any congenital heart defects, although a follow-up report by 
Hobbs et al. (24) indicated that their observations were consistent across nearly all more 
specific heart defect phenotypes. Second, we assessed serum analytes during mid-gestation – 
temporally closer to embryogenesis - rather than post-partum. These differences may 
contribute to the contrary results observed.
A recent study by Sutton and colleagues (25) also investigated gestational serum measures 
of folate (red cell), homocysteine, and B12. Their study included only 15 pregnancies 
involving conotruncal heart defects and did also not observe statistical differences in levels 
of the 3 studied analytes when compared to 568 control pregnancies.
Despite our study’s strengths of focusing on mid-gestational serum measures and a 
pathogenetically specific, the current study is not without limitations. First, collection of 
women’s serum specimens, albeit in the gestational period, was on average 8–10 weeks after 
fetal heart development. Bias due to such a single point-in-time measurement would tend to 
result in underestimation of measured effects. A related issue is that serum measures were 
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from a gestational time period when some women may have been using prenatal vitamin 
supplements. Thus, some of the measured analytes may have been directly influenced by 
such use. This use would have pertained primarily to folate, cobalamin pyridoxal 5-
phosphate, pyridoxal, pyridoxic acid, pyridoxine, and riboflavin
A second limitation is potential degradation of analytes based on collection and storage 
procedures. It has been demonstrated that folate may degrade when frozen at higher 
temperatures (−20C) than were used for samples in this study (−80C) (25). Such degradation 
would likely be nondifferential to case and control status and therefore tend to lead to 
underestimates of measured effects. Moreover, the average length of time between 
collection and frozen storage was similar between cases and controls. However, we explored 
whether even small differences between cases and controls influenced observed effects with 
analytes. Analyses that incorporated length of time into models produced similar odds ratios.
Not observing a reduced risk for conotruncal heart defects associated with higher serum 
measures of methyl donors is counter to what we hypothesized. The reasons for a lack of 
association in the current study are unknown. One might speculate that the protection 
afforded by folic acid and other one-carbon donors might no longer be operating owing to 
higher dietary levels of folic acid from fortification of the US food supply during the study 
time period.
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Table 1






No. %* No. %*
Race/Ethnicity
Hispanic 67 48.9 160 57.8
White nonHispanic 45 33.0 63 22.7
Asian 12 8.8 26 9.4
Black 8 5.8 13 4.7
Other 5 3.7 15 5.4
Age (years)
<25 41 29.3 105 37.5
25–29 37 26.4 72 25.7
30–34 40 28.6 73 26.1
≥34 22 15.7 30 10.7
*
Percentages may not equal 100 owing to missing data or rounding.
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Table 2
Mean values of selected biochemical measures in mid-pregnancy serum specimens among deliveries with 
conotruncal heart defects and deliveries without malformations, California pregnancies 2002–07.








Total homocysteine (µmol/L) 6.85 (3.72) 7.04 (4.19) −0.18 (−1.00, 0.64) 0.66
Methylmalonic acid (µmol/L) 0.14 (0.05) 0.14 (0.05) −0.00 (−0.01, 0.01) 0.45
Total cysteine (µmol/L) 220.13(41.96)
223.64
(46.85) −3.50 (−12.72, 5.71) 0.46
Methionine (µmol/L) 34.53 (7.52) 35.63 (9.46) −1.10 (−2.91, 0.70) 0.23
Serine (µmol/L) 251.98(39.26)
253.93
(49.69) −1.95 (−11.40, 7.51) 0.69
Glycine (µmol/L) 424.33(94.36)
428.72
(103.29) −4.38 (−24.81, 16.05) 0.67
Sarcosine (µmol/L) 0.58 (0.19) 0.59 (0.27) −0.02 (−0.07, 0.03) 0.52
Cystathionine (nmol/L) 0.1030(0.0390)
0.1095
(0.0595) −.0065 (−.0174, 0.0044) 0.24
Total choline (mmol/L) 3.19 (0.48) 3.12 (0.52) 0.06 (−0.04, 0.17) 0.23
Betaine (µmol/L) 16.97 (4.69) 16.89 (5.12) 0.08 (−0.93, 1.10) 0.87
Dimethylglycine (µmol/L) 1.85 (0.80) 1.86 (0.92) −0.01 (−0.19, 0.17) 0.90
Creatinine (µmol/L) 51.94 (10.19) 50.21 (8.29) 1.73 (−0.09, 3.55) 0.06
Arginine (µmol/L) 145.64(44.95)
149.10
(49.64) −3.46 (−13.25, 6.34) 0.49
Asymmetric dimethylarginine
(µmol/L) 0.47 (0.13) 0.47 (0.14) 0.00 (−0.02, 0.03) 0.77
Symmetric dimethylarginine
(µmol/L) 0.51 (0.12) 0.51 (0.10) −0.00 (−0.03, 0.02) 0.80
Homoarginine (µmol/L) 5.52 (3.06) 5.69 (2.98) −0.17 (−0.78, 0.44) 0.59






(314.44) 32.13 (−33.73, 97.99) 0.34
Pyridoxal 5-phosphate
(nmol/L) 65.40 (52.36) 69.38 (72.38) −3.97 (−17.48, 9.54) 0.57
Pyridoxal (nmol/L) 51.45 (79.23) 75.07(208.62) −23.62 (−59.53, 12.28) 0.20
Pyridoxic acid (nmol/L) 50.57 (87.25) 67.08(167.10) −16.51 (−46.12, 13.09) 0.28
Pyridoxine (nmol/L) 0.03 (0.19) 3.63 (30.76) −3.61 (−8.72, 1.51) 0.17
Riboflavin (nmol/L) 41.91 (49.23) 45.30 (42.23) −3.39 (−12.48, 5.70) 0.46
Neopterin (nmol/L) 7.96 (3.45) 7.77 (2.76) 0.19 (−0.43, 0.80) 0.55
Cotinine (nmol/L) 56.07(247.71)
29.27
(167.42) 26.80 (−13.44, 67.04) 0.19
Tryptophan (µmol/L) 73.15 (9.80) 72.74 (10.96) 0.40 (−1.75, 2.56) 0.71
Kynurenine (nmol/L) 1.21 (0.23) 1.20 (0.24) 0.02 (−0.03, 0.06) 0.53
3-Hydroxykynurenine (nmol/L) 21.17 (12.47) 19.93 (10.65) 1.24 (−1.05, 3.54) 0.29
Kynurenic acid (nmol/L) 20.33 (7.30) 19.26 (8.60) 1.06 (−0.61, 2.73) 0.21
Xanthurenic acid (nmol/L) 17.18 (8.93) 15.53 (8.94) 1.65 (−0.17, 3.47) 0.08
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Anthranilic acid (nmol/L) 20.05 (18.21) 21.03 (22.21) −0.98 (−5.24, 3.29) 0.65
3-Hydroxyanthranilic acid
(nmol/L) 23.78 (21.16) 24.59 (23.12) −0.81 (−5.39, 3.76) 0.73
Quinolinic acid (nmol/L) 326.60(105.14)
326.76
(106.91) −0.16 (−21.79, 21.47) 0.99
Nicotinic acid (nmol/L) 64.43 (16.22) 63.60 (15.08) 0.83 (−2.32, 3.98) 0.61
Nicotinamide (nmol/L) 463.53(484.35)
498.95






(132.93) −3.06 (−28.71, 22.59) 0.81
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